CalciMedica Inc. (NASDAQ:CALC) Receives $50.00 Consensus Target Price from Brokerages

Shares of CalciMedica Inc. (NASDAQ:CALC) have been assigned a consensus rating of “Hold” from the five analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $50.00.

CALC has been the subject of a number of recent analyst reports. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. Wall Street Zen lowered shares of CalciMedica from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 12th. Guggenheim assumed coverage on CalciMedica in a report on Thursday, August 20th. They set a “buy” rating on the stock. Finally, UBS Group restated a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th.

CalciMedica Stock Down 2.5%

NASDAQ:CALC opened at $1.92 on Monday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58. The firm has a market cap of $13.11 million, a P/E ratio of -0.28 and a beta of 0.83. CalciMedica has a fifty-two week low of $1.87 and a fifty-two week high of $36.00. The firm has a 50-day simple moving average of $3.03 and a two-hundred day simple moving average of $3.41.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.97. Analysts predict that CalciMedica will post -5.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other CalciMedica news, Director Fred A. Middleton purchased 49,794 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were acquired at an average price of $4.00 per share, for a total transaction of $199,176.00. Following the purchase, the director directly owned 212,654 shares of the company’s stock, valued at $850,616. The trade was a 30.57% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 28.25% of the company’s stock.

Institutional Trading of CalciMedica

A hedge fund recently raised its position in CalciMedica stock. Renaissance Technologies LLC grew its stake in shares of CalciMedica Inc. (NASDAQ:CALC) by 45.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 128,075 shares of the company’s stock after buying an additional 39,775 shares during the period. Renaissance Technologies LLC owned 0.81% of CalciMedica worth $69,000 at the end of the most recent reporting period.

About CalciMedica

CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research is centered on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead investigational product is Auxora, also known as zelnecirnon or CM4620. The selective CRAC channel inhibitor has been evaluated in clinical studies for conditions including acute pancreatitis and associated acute kidney injury, as well as other diseases involving excessive inflammation.